After almost 18 years of collaboration, Roche’s Genentech unit has ended a collaboration with AC Immune on Alzheimer’s disease therapies, handing back rights to two antibo
Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in
Roche has been given EU approval for a new formulation of its cancer immunotherapy Tecentriq that aims to make dosing easier for patients, nurses, and physicians.
Scientists at Roche and Harvard University have discovered an entirely new class of antibiotic that can kill a highly drug-resistant ‘superbug’ with a mortality rate that
A flurry of mergers and acquisitions in the pharma space at the end of 2023 ended with a $295 million deal by Roche to buy a point-of-care diagnostics platform from Lumira
Roche’s Genentech unit has looked internally for its new chief executive, appointing Ashley Magargee to the role following the departure of Alexander Hardy last month.